Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D61PGU
|
|||
| Drug Name |
PRA023
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | |
| Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [2] | ||
| Company |
Prometheus Biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial cell growth inhibitor (TNFSF15) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05013905) A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04996797) A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Prometheus Biosciences | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.